

Sudden Unexplained Death in Epilepsy

Michael R. Sperling, M.D.

Department of Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania

Sudden unexplained death in epilepsy (SUDEP) accounts for 7–17% of deaths among people with epilepsy. Both cardiac and pulmonary derangement have been postulated as proximate causes. Patients with uncontrolled seizures are at greatest risk for SUDEP, and experiencing tonic-clonic seizures, taking multiple antiepileptic drugs and having coexisting neurologic disease further increase the risk.

Mortality rates are considerably higher in people with epilepsy than would be expected in a healthy population. Sudden unexplained death (SUDEP) in epilepsy is often listed as a cause of death, accounting for 7–17% of deaths among the general population with epilepsy and perhaps 50% among patients with refractory epilepsy. (1–8) This puzzling term concisely encapsulates our lack of understanding, although not knowledge, about an important cause for excess mortality in epilepsy. This article briefly reviews what is known about SUDEP.

Criteria have been suggested by a variety of investigators to diagnose SUDEP (9,10). A reasonable synthesis would yield the following requirements:

1. The victim must have had epilepsy, defined as recurrent unprovoked seizures.
2. Death must have occurred unexpectedly, with no obvious medical cause, while in a reasonable state of health, in the absence of trauma or drowning.
3. Death must have occurred suddenly when observed.

4. There may or may not have been evidence of a seizure, but status epilepticus must not have occurred. Evidence for a seizure could consist of either a witnessed seizure or clinical evidence such as a bitten tongue or cheek.

An autopsy that does not reveal a cause for death is required for the diagnosis of definite SUDEP, whereas a diagnosis of probable SUDEP is given to those who fit the previously mentioned criteria without autopsy. Possible SUDEP would include cases in which SUDEP seems a reasonable diagnosis, but there is insufficient evidence regarding the circumstances of death and no autopsy is available.

The reported incidence of SUDEP spans a wide range, from 0.35 deaths per 1000 person-years in a population based cohort (1) to 6 deaths per 1000 person-years in a cohort with refractory epilepsy (7). In a population based study, the risk of sudden unexplained death was 24 times higher than that seen in the general population (1). Although much effort has been devoted to defining the incidence of SUDEP, there is an inherent variability in risk which relates to the nature of underlying population. The general population includes the elderly and the young, and the medically ill and the otherwise healthy; consequently the proportion of deaths from SUDEP and the SUDEP mortality rate is lower. On the other hand, cohorts chosen from epilepsy clinics or epilepsy surgery series represent the other end of the patient spectrum. These consist of otherwise healthy, relatively young individuals who have fewer other reasons to die; hence, SUDEP achieves a greater prominence as a cause of death. The underlying characteristics of epilepsy differ among the different populations as well, and as will be discussed below, this also influences the incidence of SUDEP.

Knowing the risk of SUDEP has become important because it may potentially influence whether a new drug or device is approved for marketing in the U.S. by the Food and Drug Administration (FDA). SUDEP rates have been carefully studied before or after regulatory approval (2,3,9,11), with burdens placed upon companies to demonstrate that there is no increased mortality rate associated with their product. While there is some value in defining the incidence of SUDEP, sweeping generalizations about incidence rates do not seem justified because the risk seems dependent upon individual characteristics. What characteristics are shared by patients at highest risk for SUDEP? Early studies suggested that male gender, cerebral lesions, developmental delay, a history of ongoing tonic-clonic seizures, and subtherapeutic anticonvulsant levels predominated in patients who died of SUDEP (12,13).

Address correspondence to: Dr. Michael R. Sperling, Department of Neurology, Thomas Jefferson University, Philadelphia, PA 19107; E-mail: michael.sperling@mail.tju.edu

Epilepsy Currents Vol. 1, No. 1 (September) 2001 pp. 21–23
Blackwell Science Inc.

© American Epilepsy Society

Subsequent work has yielded some conflicting data, yet certain features seem to predominate in most SUDEP series (7,8,14–17). The bulk of evidence supports the concept that patients with uncontrolled seizures are at greatest risk for SUDEP, and that patients with well controlled epilepsy, that is, no seizures, are not at increased risk. There is also a suggestion that seizure frequency may be related to risk of SUDEP, as patients with frequent seizures die more often than those with few seizures. None-the-less, it is abundantly clear that even patients with rare seizures, experiencing as few as 1 per year, are at increased risk of dying. Seizure type also influences risk. Tonic-clonic seizures convey the greatest risk of SUDEP, though sudden death can occur in the absence of tonic-clonic seizures (e.g., in patients with complex partial seizures) (1,7,8,10,16).

The relationship between SUDEP and seizures has been further elucidated in a recent study (10). SUDEP was witnessed in fifteen patients, presumably by non-medical personnel who were later interviewed. Twelve of the fifteen had a witnessed tonic-clonic seizure in association with SUDEP, and two more were in a post-ictal state at the time of death. In 12 cases, witnesses observed difficulty breathing. Resuscitation was performed in 13 of the 15 cases without success, immediately by family or staff in eight cases. SUDEP is also a phenomenon that seems to occur in the patient's domicile; two thirds of 135 patients in the series by Langan et al. (10) died while in bed, and most of the remainder died elsewhere in the home.

Concomitant neurologic illness may also influence SUDEP risk. While structural lesions were not found to be associated with SUDEP in some recent series, mental retardation, which is a marker of brain dysfunction, appears to be significant risk factor in a recent analysis (8). The mechanism underlying this remains to be elucidated, but it is consonant with the known high standardized mortality rates in retarded populations.

Anticonvulsant medication may also relate to risk of SUDEP. Initially, low medication levels were noted in autopsied cases (13), and it was suggested that poor compliance led to seizures and subsequent death. Recent studies cast doubt on this explanation. Opekin et al. (18) found no evidence for poor medication compliance or lower levels in patients who died of SUDEP than in case controls. While Nilsson et al. (15) related less frequent therapeutic drug monitoring to a higher risk, SUDEP was not associated with low serum drug levels. However, two recent studies (8,15) note an association between polytherapy and SUDEP. Patients on multiple drugs appeared to have a higher SUDEP rate. Whether this reflects a risk conveyed by antiepileptic drugs or rather the presence of more severe epilepsy remains uncertain, though some efforts were made to account for differences in seizure frequency in both series. One report (15) noted an association between

high carbamazepine levels and SUDEP; this finding should be viewed with caution, and it requires replication.

The mechanisms of death in SUDEP remain unknown, with both cardiac and pulmonary derangements having been hypothesized (19–22). There is evidence supporting cardiac arrhythmias as the terminal event. Ictal EKG studies and autopsy studies find evidence for transient ictal conduction abnormalities and myocardial injury, respectively. There are several reports documenting terminal arrhythmia or bradycardia in patients who died on monitoring units. Central apnea has also been hypothesized to produce SUDEP. There is one case report of post-ictal apnea leading to cardiac arrest, (20) and status epilepticus in sheep was associated with death from hypoventilation (23). Since both cardiac and pulmonary mechanisms can account for SUDEP, it is likely that etiology is patient and seizure dependent.

While all death is tragic, SUDEP seems especially heartbreaking since it tends to strike young, otherwise healthy individuals. Progress will be made only as risk factors are defined and mechanisms of death elucidated. Once this happens, appropriate preventative measures can be taken to minimize this complication of uncontrolled epilepsy. Until then, physicians should strive to completely control seizures, since even infrequent seizures pose risk of death.

References

1. Ficker DM. Sudden unexplained death and injury in epilepsy. *Epilepsia* 2000;41(suppl 2):S7–12.
2. Leestma JE, Annegers JF, Brodie MJ, et al. Sudden unexplained death in epilepsy: observations from a large clinical development program. *Epilepsia* 1997;38:47–55.
3. Annegers JF, Coan SP, Hauser WA, Leestma J, Duffell W, Tarver B. Epilepsy, vagal nerve stimulation by the NCP system, mortality, and sudden, unexplained death. *Epilepsia* 1998;39:206–212.
4. Annegers JF. Mortality risks in patients with epilepsy. In: Engel JJ, Pedley TA, eds. *Epilepsy: a comprehensive textbook*. Philadelphia: Lippincott-Raven Press, 1998:99–104.
5. Nashef L, Fish DR, Garner S, Sander JW, Shorvon SD. Sudden death in epilepsy: a study of incidence in a young cohort with epilepsy and learning difficulty. *Epilepsia* 1995;36:1187–1189.
6. Klenerman P, Sander JW, Shorvon SD. Mortality in patients with epilepsy: a study of patients in long term residential care. *J Neurol Neurosurg Psychiatry* 1993;56:149–152.
7. Sperling MR, Feldman H, Kinman J, Liporace JD, O'Connor MJ. Seizure control and mortality in epilepsy. *Ann Neurol* 1999;46:45–50.
8. Walczak TS, Leppik IE, D'Amelio M, Rarick J, So E, Ahman P, Ruggles K, Cascino GD, Annegers JF, Hauser WA. Incidence and risk factors in sudden unexpected death in epilepsy: a prospective cohort study. *Neurology* 2001;56:519–525.
9. Annegers JF, Coan SP, Hauser WA, Leestma J. Epilepsy, vagal nerve stimulation by the NCP system, all-cause mortality, and sudden, unexpected, unexplained death. *Epilepsia* 2000;41:549–553.
10. Langan Y, Nashef L, Sander JW. Sudden unexpected death in epi-

- lepsy: a series of witnessed deaths. *J Neurol Neurosurg Psychiatry* 2000;68:211–213.
11. Leppik IE. Tiagabine: the safety landscape. *Epilepsia* 1995;36(suppl 6):S10–13.
 12. Leestma JE, Kalelkar MB, Teas SS, Jay GW, Huges JR. Sudden unexpected death associated with seizures: analysis of 66 cases. *Epilepsia* 1984;25:84–88.
 13. Leestma JE, Walczak JR, Kalelkar MB, Teas SS. A prospective study on sudden unexpected death in epilepsy. *Ann Neurol* 1989;26:195–203.
 14. Nilsson L, Farahmand BY, Persson PG, Thiblin I, Tromson T. Risk factors for sudden unexpected death in epilepsy: a case-control study. *Lancet* 1999;353:888–893.
 15. Nilsson L, Bergman U, Diwan V, Farahmand BY, Persson PG, Tomson T. Antiepileptic drug therapy and its management in sudden unexpected death in epilepsy: a case-control study. *Epilepsia* 2001;42:667–673.
 16. Opeskin K, Thomas A, Berkovic SF. Does cardiac conduction pathology contribute to sudden unexpected death in epilepsy? *Epilepsy Res* 2000;40:17–24.
 17. Kloster R, Engelskjon T. Sudden unexpected death in epilepsy (SUDEP): a clinical perspective and a search for risk factors. *J Neurol Neurosurg Psychiatry* 1999;4:439–444.
 18. Opeskin K, Burke MB, Cordner SM, Berkovic SF. Comparison of antiepileptic drug levels in sudden unexpected deaths in epilepsy with deaths from other causes. *Epilepsia* 1999;40:1795–1798.
 19. Lathers CM, Schraeder PL, Boggs JG. Sudden unexplained death and autonomic dysfunction. In: Engel JJ, Pedley TA, eds. *Epilepsy: a comprehensive textbook*. Philadelphia: Lippincott-Raven Press, 1997:1943–1955.
 20. So EL, Sam MC, Lagerlund TL. Postictal central apnea as a cause of SUDEP: evidence from near-SUDEP incident. *Epilepsia* 2000;41:1994–1997.
 21. Dashieff RM. Sudden unexpected death in epilepsy: a series from an epilepsy surgery program and speculation of the relationship to sudden cardiac death. *J Clin Neurophysiol* 1991;8:216–222.
 22. Nei M, Sperling MR. EKG abnormalities during partial seizures in refractory epilepsy. *Epilepsia* 2000;41:542–548.
 23. Johnston SC, Horn JK, Valente J, Simon RP. The role of hyperventilation in a sheep model of epileptic sudden death. *Ann Neurol* 1995;37:531–537.